Skip to main
HUMA

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte is a promising biotechnology company with a strong pipeline that includes indications with significant market potential. Their partnership with Fresenius and access to VA hospitals provide a competitive advantage in the market. Their focus on physician support and medical education to drive sales is a smart strategy and could lead to faster uptake of their products. However, there is still a risk of slow adoption and competition from existing therapies that could affect their performance. With a diversified approach and potential for future partnerships, Humacyte has a bright future and is currently undervalued, making it a good buy for investors.

Bears say

Humacyte is a biotechnology company with a diversified pipeline of acellular tissues to treat various diseases and conditions. However, the company has yet to generate profits and may require additional funding to continue development. There is also risk associated with clinical trials and unpredictable regulatory timelines, which could delay approval. Additionally, the company's success in gaining market traction has been slow, with challenges in obtaining VAC approvals and competing with alternative products. Overall, given these factors, the outlook for Humacyte's stock is negative.

Humacyte (HUMA) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Buy based on their latest research and market trends.

According to 7 analysts, Humacyte (HUMA) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.